ArticleWorld journal of clinical cases2025
Monitoring high-risk patients for chemotherapy-related cardiotoxicity: A retrospective analysis.
Article in World journal of clinical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chemotherapy-related cardiotoxicity: Bridging the gap between evidence and practice.World journal of clinical cases · 2025Article
- Perspectives on monitoring and diagnosis of chemotherapy-induced cardiotoxicity.World journal of clinical cases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer incidence remains a global challenge. The World Health Organization reported 19976499 new cases in 2022, including 1551060 in Latin America and the Caribbean. While chemotherapy advances have improved survival, these treatments carry significant risks, particularly cardiovascular complications impacting morbidity and mortality. Early cardiotoxicity detection enables targeted interventions, guiding clinical decisions on treatment adjustments to mitigate damage and preserve function. Cardiac imaging and biomarkers assess cardiotoxicity before, during, and after therapy. Despite their importance, the lack of a structured multidisciplinary program hinders early detection and management in high-risk patients.
aimTo evaluate the use of diagnostic tools for monitoring cardiotoxicity in cancer patients receiving high-risk chemotherapy at the National University Hospital of Colombia.
methodsThis observational, retrospective cohort study included patients aged ≥ 18 with cancer treated with potentially cardiotoxic chemotherapy at the National University Hospital of Colombia (2016-2019). Data from medical records included demographics, comorbidities, biomarkers, and echocardiographic parameters. Cardiotoxicity was defined by reduced left ventricular ejection fraction (LVEF) using Simpson's method and biomarker abnormalities. Statistical analysis included descriptive methods to compare pre- and post-chemotherapy use of biomarkers and echocardiographic parameters.
resultsFrom a total of 195 patients analyzed, 8.7% (
conclusionThis study highlights the utility of echocardiography and biomarkers in assessing cardiotoxicity in oncology patients, emphasizing the need for standardized protocols to optimize early diagnosis and management. However, the retrospective nature of the study and the insufficient use of biomarkers may limit the generalizability of the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.